研究单位：[1]Beijing Dayspring Pharmaceutical Technology Co., Ltd[2]Beijing Tongren Hospital Affiliated to Capital Medical University,Beijing 1816670,Beijing Municipality 2038349,China[3]China-Japan Friendship Hospital,Beijing 1816670,Beijing Municipality 2038349,China[4]Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan 1791247,Hubei 1806949,China[5]Xiangya Hospital of Central South University,Changsha 1815577,Hunan 1806691,China[6]Jiangxi Provincial Dermatology Hospital,Nanchang 1800163,Jiangxi 1806222,China[7]Huashan Hospital Affiliated to Fudan University,Shanghai 1796236,Shanghai Municipality 1796231,China[8]Hangzhou First People''s Hospital,Hangzhou 1808926,Zhejiang 1784764,China[9]Peking University People''s Hospital,Beijing 1816670,China
The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety of CG2001 at the target dose.
